Celldex Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Celldex Therapeutics sits in the top decile of US sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count).
Celldex Therapeutics: 42 sponsored US clinical trials, 3 recruiting.
Celldex Therapeutics sponsors 42 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 25 completed. 5 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Spontaneous Urticaria, with 3 trials.
Top-decile sponsor footprint
Celldex Therapeutics ranks in the top decile of sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 34 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
42 total, page 1 of 1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
NCT07330778
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392
A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552
A Phase I Study of CDX-622
NCT06650761
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT05774184
A Study of CDX-585 in Patients With Advanced Malignancies
NCT05788484
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT05405660
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT05368285
A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT04944862
A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
NCT05031624
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT04538794
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT04440943
A Phase 1 Study of CDX-0159
NCT04146129
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT03254927
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT03329950
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
NCT02837991
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
NCT02642016
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
NCT02473731
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT02543645
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
NCT02456701
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT02386111
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT02413827
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
NCT02335918
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT02302339
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT02200380
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
NCT02014909
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
NCT01997333
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
NCT01791686
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT01498328
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT01480479
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT01460134
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT01465139
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT01156753
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
NCT01094496
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT00948961
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
NCT00458601
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
NCT00648102
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT00709462
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 13 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Celldex Therapeutics pipeline
3 recruiting of 42 indexed (7% open); 25 completed (60%).
Phase mix: 5 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Chronic Spontaneous Urticaria (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Celldex Therapeutics: open-pipeline peers nationwide
Peers matched on 42 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Celldex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 42 trials (± recruiting share)
- Academic and Community Cancer Research United · 42 trials · 14% recruiting
- Ascensia Diabetes Care · 42 trials · 0% recruiting
- Avid Radiopharmaceuticals · 42 trials · 0% recruiting
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 42 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
- Minneapolis Veterans Affairs Medical Center · 7% recruiting · 28 trials
Related
What to do with this Celldex Therapeutics page
42 registered trials is a research-attention snapshot, not an endorsement of Celldex Therapeutics or any single study.
- 3 of Celldex Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Spontaneous Urticaria is the condition Celldex Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Spontaneous Urticaria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Celldex Therapeutics pipeline card: 42 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.